Electronic Aspirin Market Identifies the Key Drivers of Growth and Challenges of the Key Industry Players
The global electronic aspirin market is expected to witness considerable
growth during the forecast period due to the increasing headache, stress
related work and rise in demand for advanced medical devices. Electronic
aspirin is a novel technology that aims to reduce pain in conditions such as
migraines, cluster headaches and other head and facial pain. The key end user
in the electronic aspirin market include hospitals, ambulatory surgical centers
(ASCs) and others.
Aspirin is
the most accepted brand available in the market for headache and pain and has
been extended to be used for heart attack and stroke. Electronic aspirin
relieves pain through nerve stimulated implantable device and is used to block
the Sphenopalatine Ganglion Signals (SPG), which is a group of nerve cells
associated with the trigeminal nerve and is characterized with the
identification of headache disorders in humans. Electronic aspirin is implanted
permanently in the upper gum on the side of head severely affected by headache.
The implant tip will connect to the SPG bundle, whenever patient feels
headache, the device would help through remote control for pain relief.
Request
to Get the Sample Pages at:
Electronic
aspirin is still under clinical development and seeking approval from the
United States Food Drug and Administration (USFDA). In addition to increasing
future expectation for electronic aspirin market is driven by, increasing
prevalence of headaches, rising healthcare expenditure and high demand for advanced
medical devices. In developed countries, increase investment in research and
development will further boost the growth of electronic aspirin market.
Currently,
only Autonomic Technologies Inc (ATI) is investing in the development of electronic aspirin. The company is mainly focusing on
the development of new therapies for treatment of cluster headaches. For
instance, in March 2017, ATI received an expanded indication (CE mark) in the
Europe for the Pulsante SPG Microstimulator system to include pain relief for
highly affected migraine patients. The Pulsante Microstimulator System provides
on demand stimulation of the SPG, which is known for cluster headache and migraine.
It is the first implantable neuro stimulation therapy to receive CE mark for
headache and migraine related pain reliefs.
Comments
Post a Comment